142 related articles for article (PubMed ID: 37861752)
1. Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study.
Kim JW; Jung HK; Lee B; Shin CM; Gong EJ; Hong J; Youn YH; Lee KJ
Eur J Clin Pharmacol; 2023 Dec; 79(12):1699-1708. PubMed ID: 37861752
[TBL] [Abstract][Full Text] [Related]
2. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
Seo SI; Park CH; You SC; Kim JY; Lee KJ; Kim J; Kim Y; Yoo JJ; Seo WW; Lee HS; Shin WG
Gut; 2021 Nov; 70(11):2066-2075. PubMed ID: 33975868
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
Gong EJ; Jung HK; Lee B; Hong J; Kim JW; Shin CM; Youn YH; Lee KJ
Aliment Pharmacol Ther; 2023 Oct; 58(7):668-677. PubMed ID: 37589510
[TBL] [Abstract][Full Text] [Related]
4. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
5. Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication.
Arai J; Miyawaki A; Aoki T; Niikura R; Hayakawa Y; Fujiwara H; Ihara S; Fujishiro M; Kasuga M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1217-1225.e6. PubMed ID: 38354970
[TBL] [Abstract][Full Text] [Related]
6. Use of proton pump inhibitors for the risk of gastric cancer.
Gao H; Li L; Geng K; Teng C; Chen Y; Chu F; Zhao Y
Medicine (Baltimore); 2022 Dec; 101(49):e32228. PubMed ID: 36626449
[TBL] [Abstract][Full Text] [Related]
7. Risk of systemic autoimmune diseases in gastric disease patients with proton pump inhibitor use: a nationwide cohort study in Taiwan.
Chen HY; Lin JJ; Yang B; Lin MC
Clin Rheumatol; 2020 Sep; 39(9):2773-2780. PubMed ID: 32152918
[TBL] [Abstract][Full Text] [Related]
8. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for
Cheung KS; Chan EW; Wong AYS; Chen L; Wong ICK; Leung WK
Gut; 2018 Jan; 67(1):28-35. PubMed ID: 29089382
[TBL] [Abstract][Full Text] [Related]
9. Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies.
Pan S; Thrift AP; Akhdar G; El-Serag HB
Dig Dis Sci; 2023 Sep; 68(9):3732-3744. PubMed ID: 37432532
[TBL] [Abstract][Full Text] [Related]
10. The Risk of Epilepsy after Long-term Proton Pump Inhibitor Therapy.
Liang CS; Bai YM; Hsu JW; Huang KL; Ko NY; Tsai CK; Yeh TC; Chu HT; Tsai SJ; Chen TJ; Chen MH
Seizure; 2021 Apr; 87():88-93. PubMed ID: 33735722
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients.
Snir Y; Leibovitzh H; Leibovici-Weissman Y; Vilkin A; Cohen AD; Shochat T; Niv Y; Dotan I; Feldhamer I; Boltin D; Levi Z
United European Gastroenterol J; 2021 Apr; 9(3):343-353. PubMed ID: 32962566
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
[TBL] [Abstract][Full Text] [Related]
14. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
15. The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy.
Ho CT; Fu CC; Tan EC; Kao WY; Lee PC; Huang YH; Huo TI; Hou MC; Wu JC; Su CW
J Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38864669
[TBL] [Abstract][Full Text] [Related]
16. Use of Proton Pump Inhibitors and the Risk for the Development of Gastric Cancers: A Nationwide Population-Based Cohort Study Using Balanced Operational Definitions.
Gong EJ; Bang CS; Kim DK; Lee JJ; Baik GH
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291956
[TBL] [Abstract][Full Text] [Related]
17. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors.
Schneider JL; Kolitsopoulos F; Corley DA
Aliment Pharmacol Ther; 2016 Jan; 43(1):73-82. PubMed ID: 26541643
[TBL] [Abstract][Full Text] [Related]
18. Association between proton pump inhibitors use and risk of asthma in Korea: A prevalent new-user cohort study.
Lim HJ; Oh IS; Noh Y; Yon DK; Shin JY
Medicine (Baltimore); 2024 Jan; 103(1):e36772. PubMed ID: 38181266
[TBL] [Abstract][Full Text] [Related]
19. Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study.
Hwang IC; Chang J; Park SM
PLoS One; 2018; 13(9):e0203918. PubMed ID: 30208110
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
